Partners

The following partnerships are focused on the discovery and development of novel Anticalin therapeutics

On January 05, 2017, Pieris and Servier, the second largest independent international pharmaceutical company headquartered in France with annual sales of more than EUR4 billion, entered into a broad strategic co-development alliance in Immuno-Oncology. Under the collaboration, Pieris and Servier will initially pursue five bispecific therapeutic programs, led by Pieris’ preclinical PRS-332 program, a potentially best-in-class PD-1-targeting bispecific checkpoint inhibitor aimed at simultaneously blocking two immune checkpoints co-expressed on exhausted T cells to further improve on existing PD-1 therapies. The four additional committed programs may combine antibodies from the Servier portfolio with Anticalin proteins based on Pieris’ proprietary platform to generate highly innovative immuno-oncology bispecific drug candidates. The alliance may be expanded to a total of eight immuno-oncology programs and Pieris has the option to co-develop and retain full commercial rights in the United States for four of these programs, including PRS-332.

Read the full press release here

On February 27, 2017, Pieris and ASKA Pharmaceutical, an independent Japanese pharmaceutical company with annual sales of approximately $400 million, entered into an option agreement for Pieris’ anemia program PRS-080. Under the terms of the agreement, ASKA has the exclusive option to license commercial rights to PRS-080 in Japan and certain other Asian countries after the completion of the planned Phase 2a study conducted by Pieris, which is scheduled to be completed in H2 2017.

Read the full press release here.

On December 08, 2015, Pieris and Roche entered into a research collaboration and license agreement in immuno-oncology. Pieris will discover Anticalin®-based drug candidates against an undisclosed target. Roche and Pieris will evaluate different drug formats against this target and advance them through preclinical development, with Roche being responsible for IND-enabling activities, clinical development and worldwide marketing of any resulting products. This collaboration represents Pieris' first partnered immuno-oncology program and leverages Pieris' capability to address a target in multiple ways through Anticalin-based drug candidates in different formats.
In September 2010, the company signed a multi-year, multi-target collaboration with both Sanofi (formerly Sanofi-aventis) and Sanofi Pasteur across a broad spectrum of indications. In April 2013 the partnership was expanded to include a novel multispecific Anticalin® program under the existing framework of the 2010 agreement.
On April 12, 2011, Pieris announced the initiation of a therapeutic discovery and development partnership with Daiichi Sankyo in which the company will produce novel Anticalin proteins against two Daiichi Sankyo targets. To date the company has achieved eight milestones in this collaboration.
In October 2013, Pieris initiated a collaboration with Zydus Cadila for the development and commercialization of novel Anticalin®-based protein therapeutics. Zydus will be responsible for IND-enabling studies, GMP manufacturing and clinical development in certain emerging markets, while Pieris will maintain rights for the co-developed compounds in key major markets.